Science & ResearchAug 12, 2026
Biomarkers of nivolumab benefit in resectable non-small cell lung cancer.
Perioperative nivolumab significantly improved event-free survival (EFS) compared with placebo in patients with resectable non-small cell lung cancer (NSCLC) in the CheckMate 77T study (ClinicalTrials.gov NCT04025879 ) 1 .
Perioperative nivolumab significantly improved event-free survival (EFS) compared with placebo in patients with resectable non-small cell lung cancer (NSCLC) in the CheckMate 77T study (ClinicalTrials.gov NCT04025879 ) 1 . Here, after randomization, 98 out of 229 patients who…
Sign in to learn & save →
The frontier is open to all. Sign in to learn this from first principles and save it to your knowledge base.